Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pathologic Processes 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Irinotecan 4Gemcitabine 4130-nm albumin-bound paclitaxel 4napabucasin 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3selpercatinib 2pembrolizumab 2cobimetinib 2Sunitinib 2Sorafenib 2Pemetrexed 2Paclitaxel 2Leucovorin 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Cetuximab 2Aspirin 2Ascorbic Acid 2trametinib 1repotrectinib 1pralsetinib 1osimertinib 1lutetium Lu 177 dotatate 1linifanib 1guadecitabine 1golotimod 1genexol-PM 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × ficlatuzumab × Gastrointestinal × Clear all
NCT00969410 2012-04-12

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
19 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡